摘要
肿瘤新生血管生成在癌症发生、发展和转移过程中起着重要作用。非侵入性定量和检测新生血管生成对于癌症的早期诊断以及预后评估十分重要。基于新生血管生成的分子特征,靶向分子显像在肿瘤新生血管显像与精准治疗中发挥关键作用。氨基肽酶N(APN,又称CD13)是一种在新生血管内皮细胞和部分肿瘤细胞中过量表达,而在正常组织血管中鲜有表达的多功能的膜结合外显肽酶,是新生血管显像和抗血管生成治疗的潜在靶点。通过系统分析近年来有关CD13分子靶向技术的研究,该文总结了基于CD13分子靶向显像及精准治疗的应用进展及发展趋势。
Tumor neovascularization plays an important role in the occurrence,development and metastasis of cancer.Non-invasive quantification and detection of tumor neovascularization is crucial for early diagnosis and prognosis assessment of cancer.Targeted molecular imaging has arisen in vascular targeting imaging and precise treatment based on the molecular characteristics of neovascularization.Aminopeptidase N(APN,or CD13)is a multifunctional membrane-bound exopeptidase that is overexpressed in neovascular endothelial cells and some tumor cells but rarely expressed in normal blood vessels,which makes it a potential target for tumor neovascularization imaging and anti-angiogenic therapy.This review summarizes the application progress and the future development trend of target molecular imaging and precise treatment based on CD13.
作者
武明豪
张燕燕
曹琳
张雪宁
叶兆祥
Wu Minghao;Zhang Yanyan;Cao Lin;Zhang Xuening;Ye Zhaoxiang(Department of Radiology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin and Tianjin′s Clinical Research Center for Cancer,Tianjin 300060,China)
出处
《中华核医学与分子影像杂志》
CAS
北大核心
2019年第11期688-693,共6页
Chinese Journal of Nuclear Medicine and Molecular Imaging
